Safety Study of Gene Therapy in Treating Lower Leg Ischemia

This study has been completed.
Sponsor:
Information provided by:
ViroMed Co., Ltd. dba VM BioPharma
ClinicalTrials.gov Identifier:
NCT00696124
First received: June 10, 2008
Last updated: July 21, 2010
Last verified: July 2010
  Purpose

The purpose of this study is to determine the safety, tolerability and preliminary efficacy of intramuscular injections of VM202 for subjects with critical limb ischemia.

Subjects selected for this study will have critical limb ischemia that has not responded to standard therapy with symptoms including pain at rest and/or ischemic ulcers.


Condition Intervention Phase
Critical Limb Ischemia
Genetic: VM202
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Critical Limb Ischemia

Further study details as provided by ViroMed Co., Ltd. dba VM BioPharma:

Primary Outcome Measures:
  • The incidence of adverse events through Day 365. [ Time Frame: Day1 pre-procedure, post procedure days 1, 8, 15 (pre and post procedure), 16, 21, 28, 59, 91, 180, and 365 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change from baseline in hemodynamic measurements (ABI, TBI and wave form analysis) and TcP02. [ Time Frame: Days 15, 28, 59, 91, 180, and 365 ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: March 2007
Study Completion Date: May 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
2mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
Genetic: VM202
2mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
Experimental: Cohort 2
4mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
Genetic: VM202
4mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
Experimental: Cohort 3
8mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
Genetic: VM202
8mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
Experimental: Cohort 4
16mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
Genetic: VM202
16mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Detailed Description:

The study will consist of four (4) cohorts with a total of 3 subjects enrolled in each cohort to VM202.For each dose cohort, VM202 will be administered as a local intramuscular injection in 2 divided doses with a 2-week interval between the injections. Preliminary efficacy (hemodynamic assessments), safety and tolerability will be evaluated at Baseline (screening) and at designated time points throughout the study.

After all subjects in the first dose cohort have completed the 30-day (+ 2 days) follow-up visit following the first dose of the study drug, an interim safety evaluation will be performed with the submission of safety data to the Data Safety Monitoring Committee (DSMC). If the DSMC recommends continuing the study, the second dose cohort will be treated. This process will be repeated between the second and third dose cohort and between the third and fourth dose cohort.

All four dose cohorts will be followed for up to 5 years from the time of the first dose of study drug administration.

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, between 20 and 90 years of age
  • Have critical limb ischemia (Rutherford Class 4 and 5) and considered not a candidate for bypass graft surgery or percutaneous angioplasty due to comorbid conditions, failure of previous surgical or interventional procedures or caliber of grafting arteries. Critical Limb ischemia is defined as

    1. Stable symptoms on standard therapy including anti-platelet agents, vascular rheologic agents, cilostazol, anticoagulant and pain medication for 30 days.
    2. Pain at rest and/or ischemic ulcers for a minimum of 4 weeks.
  • Have diagnostic angiography of the affected limb in the last 12 months demonstrating a significant occlusion of one more of the following arteries: iliac, superficial femoral, popliteal, and one or more infra-popliteal arteries.
  • Have a resting ankle systolic pressure (in either the dorsalis pedis or posterior tibial arteries) of less than or equal to 60mmHg or a resting toe systolic pressure of less than or equal to 40 mmHg in the affected limb.
  • Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study including anti-platelet and statin (CoA Reductase) inhibitor treatment
  • Be capable of understanding and complying with the protocol and signing the informed consent document prior to being subjected to any study related procedures
  • Women who are surgically sterile or at least 1 year postmenopausal or who have been practicing adequate contraception for at least 12 weeks prior to entering the study. If the subject is of child-bearing potential, she must have a negative serum pregnancy test result during the study.
  • If the subject or the subject's partner(s) is of child bearing potential, the subject and the subject's partner(s) must agree to use a "double barrier" method of birth control while participating in this study.

Exclusion Criteria:

  • Subjects who have undergone a revascularization procedure or sympathectomy within 12 weeks prior to study entry that remains patent. A failed revascularization procedure in the previous 4 weeks is acceptable.
  • Subjects with grade 3 (hemorrhages, exudates) or grade 4 (papilledema) retinopathy.
  • Subjects currently receiving immunosuppressive medications, chemotherapy, radiation therapy.
  • Subject with aorto-iliac occlusion (greater than 75%).
  • Subjects that will require amputation within 4 weeks of randomization.
  • Subjects with any co-morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 6 months
  • Subjects with history of drug (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 3 months.
  • Subjects with a current history or new screening finding of malignant neoplasm except for basal cell carcinoma of the skin and squamous cell carcinoma of the skin (if excised and no evidence of recurrence).
  • Subjects with evidence of active infection (e.g. cellulitis, osteomyelitis) or deep ulceration exposing bone or tendon in the extremity planned for treatment.
  • Subjects with a clinically significant abnormality in routine hematology, urinalysis, chemistry, liver function or other laboratory tests, including HIV, Hepatitis B (HepBSAg), Cytomegalovirus (CMV), hepatitis C virus (HCV), Venereal Disease Research Laboratory test (VDRL), prostate-specific antigen (PSA), and chorio-embryonic antigen (CEA), or signs of malignant neoplasm by radiological imaging tests, including chest radiograph at Screening or Day 1. Specific laboratory exclusion criteria include the following:

    1. Hemoglobin less than 9.0 G/dl
    2. WBC count less than 3,000
    3. Platelet count less than 75,000
    4. Fasting glucose greater than 250 mg/dl
    5. AST and/or ALT greater than 3X upper limit of normal
  • Subjects with any other condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation.
  • Subjects unable or unwilling to comply with the protocol or to cooperate fully with the investigator or site personnel.
  • Subjects that have received any other investigational drug within the 30 days prior to study drug administration or will receive such a drug during the timeframe of this study.
  • Subjects with uncontrolled hypertension defined as systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 115 mmHg at Baseline evaluation.
  • Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites or bleeding varices.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00696124

Locations
United States, Minnesota
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital
Minneapolis, Minnesota, United States, 55407
Sponsors and Collaborators
ViroMed Co., Ltd. dba VM BioPharma
Investigators
Principal Investigator: Timothy Henry, MD Minneapolis Heart Institute Foundation
  More Information

No publications provided

Responsible Party: Sheila Yi/Director, Business Development, ViroMed Co., Ltd.
ClinicalTrials.gov Identifier: NCT00696124     History of Changes
Other Study ID Numbers: US 06-1-001
Study First Received: June 10, 2008
Last Updated: July 21, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by ViroMed Co., Ltd. dba VM BioPharma:
lower leg ischemia
peripheral artery disease

Additional relevant MeSH terms:
Ischemia
Pathologic Processes

ClinicalTrials.gov processed this record on July 28, 2014